Your browser doesn't support javascript.
loading
Direct Current Cardioversion of Atrial Fibrillation in Patients With Left Atrial Appendage Occlusion Devices.
Sharma, Sharan Prakash; Turagam, Mohit K; Gopinathannair, Rakesh; Reddy, Vivek; Kar, Saibal; Mohanty, Sangamitra; Cheng, Jie; Holmes, David R; Sondergaard, Lars; Natale, Andrea; Lakkireddy, Dhanunjaya.
Affiliation
  • Sharma SP; Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas.
  • Turagam MK; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Gopinathannair R; Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas.
  • Reddy V; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Kar S; Cedars-Sinai Medical Center, Los Angeles, California.
  • Mohanty S; Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas.
  • Cheng J; Texas Heart Institute, St. Luke's Hospital, Houston, Texas.
  • Holmes DR; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
  • Sondergaard L; The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Natale A; Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas.
  • Lakkireddy D; Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas. Electronic address: dlakkireddy@gmail.com.
J Am Coll Cardiol ; 74(18): 2267-2274, 2019 11 05.
Article in En | MEDLINE | ID: mdl-31672183
ABSTRACT

BACKGROUND:

Direct current cardioversion (DCCV) is a common rhythm control strategy in patients with symptomatic atrial fibrillation or flutter. There is no long-term data regarding the safety of DCCV in patients with endocardial left atrial appendage occlusion (LAAO) devices.

OBJECTIVES:

The purpose of this study was to assess the feasibility and safety of DCCV in patients with an LAAO device.

METHODS:

This multicenter retrospective study included 148 patients with an LAAO device who underwent DCCV for symptomatic atrial fibrillation or atrial flutter.

RESULTS:

The average age of the included patients was 72 ± 7 years and 59% were men. All patients (100%) had a transesophageal echocardiogram prior to DCCV. Device-related thrombus was seen in 2.7%. They were all successfully treated with oral anticoagulation (OAC) and were able to undergo DCCV after 6 to 8 weeks. DCCV restored sinus rhythm in all patients. None of the patients had DCCV-related thromboembolic complications. A total of 22% of patients were newly started on OAC after DCCV. There was no difference in DCCV-related complications between patients treated with or without OAC post-DCCV. Patients receiving OAC post-DCCV were found to undergo cardioversion at an earlier time after implantation (3.6 months [interquartile range (IQR) 0.7 to 8.6 months] vs. 8.6 months [IQR 2.5 to 13.3 months]; p = 0.003). Three transient ischemic attacks, unrelated to DCCV, were found during follow-up. During a median follow-up of 12.8 months (IQR 11.8 to 14.2 months), no device or left atrial thrombosis, device dislodgement, or a new device leak were observed. One patient died during follow-up due to noncardiac cause.

CONCLUSIONS:

DCCV is feasible in high-risk AF patients with an LAAO device without the need for oral anticoagulation if pre-procedural transesophageal echocardiography shows good device position, absence of device-related thrombus, and peridevice leak of ≤5 mm. The preliminary results are encouraging, but further large studies are warranted to establish safety.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Electric Countershock / Atrial Appendage / Septal Occluder Device Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Electric Countershock / Atrial Appendage / Septal Occluder Device Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 2019 Document type: Article